JohnMartinMagenauIVMD
Hematology • Ann Arbor, MIAssistant Professor, Internal Medicine, University of Michigan Medical School
Dr. Magenau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-9814Fax+1 734-232-7580- Is this information wrong?
Education & Training
University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2004 - 2007
Lewis Katz School of Medicine at Temple UniversityClass of 2004
Certifications & Licensure
MI State Medical License 2007 - 2026
IL State Medical License 2004 - 2008- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen Start of enrollment: 2007 Oct 01
- Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Start of enrollment: 2016 Sep 19
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA phase 2 trial of CD24Fc for prevention of graft-versus-host disease.John Magenau, Samantha Jaglowski, Joseph Uberti, Sherif S Farag, Mary Mansour Riwes, Attaphol Pawarode, Sarah Anand, Monalisa Ghosh, John Maciejewski, Thomas Braun, Ma...> ;Blood. 2024 Jan 4
- Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score.Vasbinder, A., Catalan, T., Anderson, E., Chu, C., Kotzin, M., Murphy, D., Cheplowitz, H., Diaz, K., Bitterman, B., Pizzo, I., Huang, Y., Xie, J., Hoeger, C., Kaakati,...> ;Journal of the American Heart Association. 2024 Jan 2
- 4 citationsCardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors.Vasbinder, A., Hoeger, C., Catalan, T., Anderson, E., Chu, C., Kotzin, M., Xie, J., Kaakati, R., Berlin, H., Shadid, H., Perry, D., Pan, M., Takiar, R., Padalia, K., M...> ;JACC. Cardiooncology. 2023 Dec 1
- Join now to see all
Abstracts/Posters
- Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
If I’m Immunocompromised, Should I Keep Wearing My Mask Once I’m Vaccinated?May 28th, 2021
OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRJanuary 27th, 2020
A Phase II Trial of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell TransplantJanuary 21st, 2016- Join now to see all
Hospital Affiliations
University of Michigan Medical CenterAnn Arbor, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
